Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refract...
October 27, 2026
Share
Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.